Mizoribine inhibits hepatitis C virus RNA replication: Effect of combination with interferon-α

Kazuhito Naka, Masanori Ikeda, Ken Ichi Abe, Hiromichi Dansako, Nobuyuki Kato

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Interferon (IFN)-α monotherapy, as well as the more effective combination therapy of IFN-α and ribavirin, are currently used for patients with chronic hepatitis C caused by hepatitis C virus (HCV) infection, although the mechanisms of the antiviral effects of these reagents on HCV remain ambiguous, and side effects such as anemia due to the administration of ribavirin present a problem for patients who are advanced in years. Using a recently developed reporter assay system in which genome-length dicistronic HCV RNA encoding Renilla luciferase gene was found to replicate efficiently, we found that mizoribine, an imidazole nucleoside, inhibited HCV RNA replication. The anti-HCV activity of mizoribine (IC50: approximately 100 μM) was similar to that of ribavirin. Using this genome-length HCV RNA replication monitor system, we were the first to demonstrate that the combination of IFN-α and ribavirin exhibited more effective anti-HCV activity than the use of IFN-α alone. Moreover, we found that the anti-HCV activity of mizoribine in co-treatment with IFN-α was at least equivalent to that of ribavirin. This effect was apparent in the presence of at least 5 μM mizoribine. Since mizoribine is currently used in several clinical applications and has not been associated with severe side effects, mizoribine is considered to be of potential use as a new anti-HCV reagent in combination with IFN-α.

Original languageEnglish
Pages (from-to)871-879
Number of pages9
JournalBiochemical and Biophysical Research Communications
Volume330
Issue number3
DOIs
Publication statusPublished - May 13 2005

Fingerprint

Virus Replication
Viruses
Hepacivirus
Interferons
RNA
Ribavirin
Genes
Renilla Luciferases
Genome
bredinin
Chronic Hepatitis C
Virus Diseases
Nucleosides
Inhibitory Concentration 50
Antiviral Agents
Anemia
Assays
Therapeutics

Keywords

  • HCV RNA replication system
  • Hepatitis C virus
  • HuH-7
  • Interferon
  • Mizoribine
  • Ribavirin

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics
  • Molecular Biology

Cite this

Mizoribine inhibits hepatitis C virus RNA replication : Effect of combination with interferon-α. / Naka, Kazuhito; Ikeda, Masanori; Abe, Ken Ichi; Dansako, Hiromichi; Kato, Nobuyuki.

In: Biochemical and Biophysical Research Communications, Vol. 330, No. 3, 13.05.2005, p. 871-879.

Research output: Contribution to journalArticle

@article{c6d388212ebb4e3daa2ead9858dfcd93,
title = "Mizoribine inhibits hepatitis C virus RNA replication: Effect of combination with interferon-α",
abstract = "Interferon (IFN)-α monotherapy, as well as the more effective combination therapy of IFN-α and ribavirin, are currently used for patients with chronic hepatitis C caused by hepatitis C virus (HCV) infection, although the mechanisms of the antiviral effects of these reagents on HCV remain ambiguous, and side effects such as anemia due to the administration of ribavirin present a problem for patients who are advanced in years. Using a recently developed reporter assay system in which genome-length dicistronic HCV RNA encoding Renilla luciferase gene was found to replicate efficiently, we found that mizoribine, an imidazole nucleoside, inhibited HCV RNA replication. The anti-HCV activity of mizoribine (IC50: approximately 100 μM) was similar to that of ribavirin. Using this genome-length HCV RNA replication monitor system, we were the first to demonstrate that the combination of IFN-α and ribavirin exhibited more effective anti-HCV activity than the use of IFN-α alone. Moreover, we found that the anti-HCV activity of mizoribine in co-treatment with IFN-α was at least equivalent to that of ribavirin. This effect was apparent in the presence of at least 5 μM mizoribine. Since mizoribine is currently used in several clinical applications and has not been associated with severe side effects, mizoribine is considered to be of potential use as a new anti-HCV reagent in combination with IFN-α.",
keywords = "HCV RNA replication system, Hepatitis C virus, HuH-7, Interferon, Mizoribine, Ribavirin",
author = "Kazuhito Naka and Masanori Ikeda and Abe, {Ken Ichi} and Hiromichi Dansako and Nobuyuki Kato",
year = "2005",
month = "5",
day = "13",
doi = "10.1016/j.bbrc.2005.03.062",
language = "English",
volume = "330",
pages = "871--879",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Mizoribine inhibits hepatitis C virus RNA replication

T2 - Effect of combination with interferon-α

AU - Naka, Kazuhito

AU - Ikeda, Masanori

AU - Abe, Ken Ichi

AU - Dansako, Hiromichi

AU - Kato, Nobuyuki

PY - 2005/5/13

Y1 - 2005/5/13

N2 - Interferon (IFN)-α monotherapy, as well as the more effective combination therapy of IFN-α and ribavirin, are currently used for patients with chronic hepatitis C caused by hepatitis C virus (HCV) infection, although the mechanisms of the antiviral effects of these reagents on HCV remain ambiguous, and side effects such as anemia due to the administration of ribavirin present a problem for patients who are advanced in years. Using a recently developed reporter assay system in which genome-length dicistronic HCV RNA encoding Renilla luciferase gene was found to replicate efficiently, we found that mizoribine, an imidazole nucleoside, inhibited HCV RNA replication. The anti-HCV activity of mizoribine (IC50: approximately 100 μM) was similar to that of ribavirin. Using this genome-length HCV RNA replication monitor system, we were the first to demonstrate that the combination of IFN-α and ribavirin exhibited more effective anti-HCV activity than the use of IFN-α alone. Moreover, we found that the anti-HCV activity of mizoribine in co-treatment with IFN-α was at least equivalent to that of ribavirin. This effect was apparent in the presence of at least 5 μM mizoribine. Since mizoribine is currently used in several clinical applications and has not been associated with severe side effects, mizoribine is considered to be of potential use as a new anti-HCV reagent in combination with IFN-α.

AB - Interferon (IFN)-α monotherapy, as well as the more effective combination therapy of IFN-α and ribavirin, are currently used for patients with chronic hepatitis C caused by hepatitis C virus (HCV) infection, although the mechanisms of the antiviral effects of these reagents on HCV remain ambiguous, and side effects such as anemia due to the administration of ribavirin present a problem for patients who are advanced in years. Using a recently developed reporter assay system in which genome-length dicistronic HCV RNA encoding Renilla luciferase gene was found to replicate efficiently, we found that mizoribine, an imidazole nucleoside, inhibited HCV RNA replication. The anti-HCV activity of mizoribine (IC50: approximately 100 μM) was similar to that of ribavirin. Using this genome-length HCV RNA replication monitor system, we were the first to demonstrate that the combination of IFN-α and ribavirin exhibited more effective anti-HCV activity than the use of IFN-α alone. Moreover, we found that the anti-HCV activity of mizoribine in co-treatment with IFN-α was at least equivalent to that of ribavirin. This effect was apparent in the presence of at least 5 μM mizoribine. Since mizoribine is currently used in several clinical applications and has not been associated with severe side effects, mizoribine is considered to be of potential use as a new anti-HCV reagent in combination with IFN-α.

KW - HCV RNA replication system

KW - Hepatitis C virus

KW - HuH-7

KW - Interferon

KW - Mizoribine

KW - Ribavirin

UR - http://www.scopus.com/inward/record.url?scp=16244415552&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16244415552&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2005.03.062

DO - 10.1016/j.bbrc.2005.03.062

M3 - Article

C2 - 15809077

AN - SCOPUS:16244415552

VL - 330

SP - 871

EP - 879

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 3

ER -